Wednesday, October 7, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Earnings callNasdaq· December 11, 2025

Planet Labs (PL) Q3 2026 Earnings Call Transcript

View original at nasdaq.com
Planet Labs (PL) Q3 2026 Earnings Call Transcript Image source: The Motley Fool. Date Wednesday, December 10, 2025 at 5:00 p.m…
Opening lines of the source · Nasdaq · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • In ten years' time most compute will be going up to space

    80% confidence

  • Current administration emphasis on leveraging commercial tech for DOD/intelligence is a positive trend for Planet Labs

    80% confidence

  • Planet Labs is the only company with 600+ earth imaging satellites built and operated

    80% confidence

  • Satellite services pipeline has approximately 20 opportunities with focus on 6 mature deals

    80% confidence

  • AI-enabled solutions developed for government are expected to unlock future commercial growth

    80% confidence

  • Q4 2026 growth rates provide pretty good benchmark to use as a reference for FY2027

    80% confidence

  • Google's selection of Planet Labs for SunCatcher is a huge compliment to the company

    80% confidence

  • SpaceX is the only comparable company to Planet Labs for proven scaled constellation capability

    80% confidence

  • Insurance and finance are identified as massive future commercial markets for Planet Labs

    80% confidence

  • There is a lot of interest in this administration in leveraging new tech to drive real mission value

    80% confidence

  • Planet Labs is the first proven space + AI company

    80% confidence

  • Berlin manufacturing facility will double Planet Labs' manufacturing capacity

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com